Performance of a New Glucose Meter System
Performance of the TATSU/Tradewind Blood Glucose Monitoring System
1 other identifier
interventional
96
1 country
1
Brief Summary
The purpose of this study is to evaluate the performance and acceptability of a new blood glucose monitoring system, which includes meter and sensor strip.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable diabetes
Started Nov 2010
Shorter than P25 for not_applicable diabetes
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2010
CompletedFirst Submitted
Initial submission to the registry
December 18, 2010
CompletedFirst Posted
Study publicly available on registry
December 21, 2010
CompletedResults Posted
Study results publicly available
May 1, 2012
CompletedFebruary 29, 2016
January 1, 2016
1 month
December 18, 2010
April 4, 2012
January 29, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
Percent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method
Subjects with diabetes used an investigational blood glucose monitoring system (BGMS) with subject capillary blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results \<75mg/dL) or +/- 5 to 20% (for reference BG results \>=75mg/dL) of the reference method results.
2 hours
Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method
Healthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results \<75mg/dL) or +/- 5% to 20% (for reference BG results \>=75mg/dL) of the reference method results.
2 hours
Secondary Outcomes (1)
Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)
2 hours
Study Arms (1)
Intended Users of the Monitoring System
EXPERIMENTALUntrained subjects with diabetes use an investigational blood glucose monitoring system.
Interventions
Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
Eligibility Criteria
You may qualify if:
- Type 1 or 2 diabetes
- Age 18 years or older
- Routinely performs blood glucose self testing at home, at least once per day
- Able to speak, read, and understand English.
- Is willing to complete all study procedures
You may not qualify if:
- Currently pregnant
- Hemophilia or any other bleeding disorder
- Taking prescription anticoagulants or has clotting problems that may prolong bleeding. Taking aspirin daily is not excluded
- Subject employee of competitive medical device company
- Cognitive disorder or other condition, which in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AMCR Institute
Escondido, California, 92026, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Jane Wallace
- Organization
- Ascensia Diabetes Care
Study Officials
- PRINCIPAL INVESTIGATOR
Timothy Bailey, MD
AMCR Institute
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 18, 2010
First Posted
December 21, 2010
Study Start
November 1, 2010
Primary Completion
December 1, 2010
Study Completion
December 1, 2010
Last Updated
February 29, 2016
Results First Posted
May 1, 2012
Record last verified: 2016-01